<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="timothy" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">timothy</book-part-id>
      <title-group>
        <title>Timothy Syndrome</title>
        <alt-title alt-title-type="alt-title">Synonym: Long QT Syndrome with Syndactyly, Long QT Syndrome Type 8</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Napolitano</surname>
            <given-names>Carlo</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Department of Molecular Cardiology<break/>IRCCS Fondazione Salvatore Maugeri<break/>Pavia, Italy <break/>Langone Medical Center<break/>New York University<break/>New York, New York</aff>
          <email>carlo.napolitano@fsm.it</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Splawski</surname>
            <given-names>Igor</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Assistant Professor, Harvard Medical School<break/>Assistant, Children&#x02019;s Hospital Boston<break/>Boston, Massachusetts</aff>
          <email>igor@enders.tch.harvard.edu</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Timothy</surname>
            <given-names>Katherine W</given-names>
          </name>
          <degrees>BS</degrees>
          <aff>Clinical Coordinator (retired), Children's Hospital Boston<break/>Harvard Medical School<break/>Boston, Massachusetts</aff>
          <email>katherinewtimothy@gmail.com</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Bloise</surname>
            <given-names>Raffaella</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>Department of Molecular Cardiology<break/>IRCCS Fondazione Salvatore Maugeri<break/>Pavia, Italy</aff>
          <email>raffaella.bloise@fsm.it</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Priori</surname>
            <given-names>Silvia G</given-names>
          </name>
          <degrees>MD, PhD</degrees>
          <aff>Professor, Department of Cardiology<break/>University of Pavia<break/>Department of Molecular Cardiology<break/>IRCCS Fondazione Salvatore Maugeri<break/>Pavia, Italy<break/>Langone Medical Center<break/>New York University<break/>New York, New York</aff>
          <email>silvia.priori@fsm.it</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date iso-8601-date="2006-02-15" date-type="created">
          <day>15</day>
          <month>2</month>
          <year>2006</year>
        </date>
        <date iso-8601-date="2015-07-16" date-type="updated">
          <day>16</day>
          <month>7</month>
          <year>2015</year>
        </date>
        <date iso-8601-date="2009-08-20" date-type="revised">
          <day>20</day>
          <month>8</month>
          <year>2009</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="tar" document-type="chapter">Thrombocytopenia Absent Radius Syndrome</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="tbs" document-type="chapter">Townes-Brocks Syndrome</related-object>
      <abstract id="timothy.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p>Timothy syndrome is a multisystem disorder characterized by cardiac, hand/foot, facial, and neurodevelopmental features. Typical cardiac findings include a rate-corrected QT interval &#x0003e;480 ms, functional 2:1 AV block with bradycardia, tachyarrhythmias, and congenital heart defects (patent ductus arteriosus, patent foramen ovale, ventricular septal defect, tetralogy of Fallot, hypertrophic cardiomyopathy). The diagnosis of Timothy syndrome is generally made within the first few days of life although it may be suspected prenatally due to 2:1 AV block or bradycardia in the fetus. Hand/foot findings are unilateral or bilateral cutaneous syndactyly variably involving fingers two (index), three (middle), four (ring), and five (little) and bilateral cutaneous syndactyly of toes two and three. Facial findings include depressed nasal bridge, low-set ears, thin vermilion border of the upper lip, and round face. Neuropsychiatric involvement includes global developmental delays and autism spectrum disorders. Ventricular tachyarrhythmia is the leading cause of death, followed by infection and complications of intractable hypoglycemia. Average age of death is 2.5 years.</p>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Timothy syndrome is diagnosed by clinical features and by the presence of a pathogenic variant in <italic toggle="yes">CACNA1C,</italic> the gene encoding the Ca<sub>V</sub>1.2 calcium channel.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Treatment includes use of beta-blockers and/or other antiarrhythmic drugs to maintain QT interval stability to prevent ventricular tachyarrhythmia. In some instances pacemakers can be placed during the first days of life to control 2:1 AV block and resultant bradycardia, but an implantable cardioverter defibrillator to prevent sudden cardiac death should be considered in all affected persons. Treatment for congenital heart defects follows usual protocols.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Because anesthesia is a known trigger for cardiac arrhythmia, close cardiac monitoring is warranted during surgery.</p>
          <p><italic toggle="yes">Surveillance:</italic> Monitoring of serum glucose concentrations, especially in individuals treated with beta-blockers, which may mask hypoglycemic symptoms.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Drugs reported to prolong QT interval; drugs and dietary practices that could lead to hypoglycemia.</p>
          <p><italic toggle="yes">Evaluation of relatives at risk:</italic> Although Timothy syndrome usually occurs as a result of a <italic toggle="yes">de novo</italic> pathogenic variant, in rare instances sibs could be affected because of parental germline mosaicism; thus, monitoring of fetal cardiac rate and function during at-risk pregnancies is warranted.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>Due to high mortality Timothy syndrome often results from a <italic toggle="yes">de novo</italic> pathogenic variant. The risk to sibs of a proband is small; however, because parental germline mosaicism occurs, the sibs of a proband may be at increased risk of inheriting a <italic toggle="yes">CACNA1C</italic> pathogenic variant. Prenatal testing is possible for pregnancies at increased risk in families in which the pathogenic variant has been identified.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="timothy.Diagnosis">
        <title>Diagnosis</title>
        <p>Timothy syndrome is a multisystem disorder characterized by cardiac, hand, facial, and neurodevelopmental features caused by pathogenic variants in the Ca<sub>V</sub>1.2 L-type calcium channel gene, <italic toggle="yes">CACNA1C</italic>.</p>
        <sec id="timothy.Suggestive_Findings">
          <title>Suggestive Findings</title>
          <p>Diagnosis of Timothy syndrome should be suspected in individuals with the following two features:</p>
          <list list-type="bullet">
            <list-item>
              <p>A rate-corrected QT (QTc) interval &#x0003e;480 ms</p>
            </list-item>
            <list-item>
              <p>Unilateral or bilateral cutaneous syndactyly variably involving fingers two (index), three (middle), four (ring), and five (little) and bilateral cutaneous syndactyly of toes two and three</p>
            </list-item>
          </list>
          <p><bold>Additional findings</bold> that may be present:</p>
          <list list-type="bullet">
            <list-item>
              <p>Congenital heart defects (patent ductus arteriosus [PDA], patent foramen ovale [PFO], ventricular septal defect [VSD], tetralogy of Fallot [TOF], hypertrophic cardiomyopathy [HCM]) (in ~61% of individuals)</p>
            </list-item>
            <list-item>
              <p>Facial anomalies including depressed nasal bridge, low-set ears, thin vermilion of the upper lip, round face (in ~85% of individuals)</p>
            </list-item>
            <list-item>
              <p>Neurologic symptoms including autism, seizures, intellectual disability, hypotonia</p>
            </list-item>
          </list>
        </sec>
        <sec id="timothy.Establishing_the_Diagnosis">
          <title>Establishing the Diagnosis</title>
          <p>The diagnosis of Timothy syndrome is established in a proband with the identification of a pathogenic variant in <italic toggle="yes">CACNA1C</italic> (see <xref ref-type="table" rid="timothy.T.molecular_genetic_testing_used">Table 1</xref>).</p>
          <p><bold>Molecular testing approaches</bold> may include the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Targeted analysis for pathogenic variants of <italic toggle="yes">CACNA1C</italic>, followed by sequence analysis if no pathogenic variant is found</p>
            </list-item>
            <list-item>
              <p>Sequence analysis of <italic toggle="yes">CACNA1C</italic>, followed by gene-targeted deletion/duplication analysis if no pathogenic variant is found</p>
            </list-item>
            <list-item>
              <p>Use of a multi-gene panel that includes <italic toggle="yes">CACNA1C</italic> and other genes of interest (see <xref ref-type="sec" rid="timothy.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
            </list-item>
          </list>
          <table-wrap id="timothy.T.molecular_genetic_testing_used" position="anchor" orientation="portrait">
            <label>Table 1. </label>
            <caption>
              <p>Molecular Genetic Testing Used in Timothy Syndrome</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                  <th id="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                  <th id="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">
                    <italic toggle="yes">CACNA1C</italic>
                  </td>
                  <td headers="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted analysis for pathogenic variants</td>
                  <td headers="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>4</sup></td>
                  <td headers="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">100%&#x000a0;<sup>5</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gene-targeted deletion/duplication analysis&#x000a0;<sup>6</sup></td>
                  <td headers="hd_h_timothy.T.molecular_genetic_testing_used_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown; none reported&#x000a0;<sup>7</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="timothy.TF.1.1">
                <label>1. </label>
                <p>See <related-object source-id="gene" document-id="timothy" object-id="timothy.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein.</p>
              </fn>
              <fn id="timothy.TF.1.2">
                <label>2. </label>
                <p>See <xref ref-type="sec" rid="timothy.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
              </fn>
              <fn id="timothy.TF.1.3">
                <label>3. </label>
                <p>All 16 individuals with classic Timothy syndrome in whom molecular genetic testing was performed had the same pathogenic variant, <xref ref-type="table" rid="timothy.T.selected_cacna1c_pathogenic_al">p.Gly406Arg</xref>, in exon 8A of <italic toggle="yes">CACNA1C</italic> [<xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>].</p>
              </fn>
              <fn id="timothy.TF.1.4">
                <label>4. </label>
                <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
              </fn>
              <fn id="timothy.TF.1.5">
                <label>5. </label>
                <p><xref ref-type="bibr" rid="timothy.REF.gillis.2012.182">Gillis et al [2012]</xref> reported a pathogenic variant in exon 38.</p>
              </fn>
              <fn id="timothy.TF.1.6">
                <label>6. </label>
                <p>Gene-targeted deletion/duplication analysis detects intragenic deletions or duplications. Methods that may be used can include: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a gene-targeted microarray designed to detect single-exon deletions or duplications.</p>
              </fn>
              <fn id="timothy.TF.1.7">
                <label>7. </label>
                <p>No deletions or duplications of <italic toggle="yes">CACNA1C</italic> have been reported to cause Timothy syndrome. No data on detection rate of gene-targeted deletion/duplication analysis are available.</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
        </sec>
      </sec>
      <sec id="timothy.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="timothy.Clinical_Description">
          <title>Clinical Description</title>
          <p>Phenotypic features of Timothy syndrome are summarized in <xref ref-type="table" rid="timothy.T.cardiac_phenotype_of_classic_t">Table 2</xref> and <xref ref-type="table" rid="timothy.T.extracardiac_phenotype_of_timo">Table 3</xref> [<xref ref-type="bibr" rid="timothy.REF.reichenbach.1992.54">Reichenbach et al 1992</xref>; <xref ref-type="bibr" rid="timothy.REF.marks.1995a.744">Marks et al 1995a</xref>; <xref ref-type="bibr" rid="timothy.REF.marks.1995b.59">Marks et al 1995b</xref>; <xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>; <xref ref-type="bibr" rid="timothy.REF.loanjoe.2005.1365">Lo-A-Njoe et al 2005</xref>; Timothy 2005, personal communication; Bloise 2006, personal communication].</p>
          <sec id="timothy.Cardiac_Manifestations">
            <title>Cardiac Manifestations</title>
            <p><bold>Long QT interval.</bold> In addition to QT interval prolongation, electrocardiographic manifestations that are common in individuals with Timothy syndrome and rare in other long QT syndromes (LQTSs) include:</p>
            <list list-type="bullet">
              <list-item>
                <p>Atrioventricular (AV) block. The 2:1 AV block is likely caused by the extremely prolonged ventricular repolarization and refractory periods and not by AV node malfunction.</p>
              </list-item>
              <list-item>
                <p>Macroscopic T-wave alternans: Positive and negative T waves on a beat-to-beat basis. This ECG pattern may also be observed in individuals with LQTS type 3 <italic toggle="yes">(SCN5A</italic> pathogenic variant) and marked prolongation of the QT interval.</p>
              </list-item>
            </list>
            <p><bold>Age at diagnosis.</bold> In general, the diagnosis of Timothy syndrome is made within the first few days of life based on the markedly prolonged rate-corrected QT interval including bradycardia and 2:1 AV block [<xref ref-type="bibr" rid="timothy.REF.reichenbach.1992.54">Reichenbach et al 1992</xref>, <xref ref-type="bibr" rid="timothy.REF.marks.1995a.744">Marks et al 1995a</xref>, <xref ref-type="bibr" rid="timothy.REF.loanjoe.2005.1365">Lo-A-Njoe et al 2005</xref>]. Rarely, diagnosis may be delayed until age two to four years [<xref ref-type="bibr" rid="timothy.REF.marks.1995b.59">Marks et al 1995b</xref>, <xref ref-type="bibr" rid="timothy.REF.splawski.2005.8089">Splawski et al 2005</xref>].</p>
            <p>Occasionally, the diagnosis of Timothy syndrome is suspected prenatally because of fetal distress secondary to cardiac findings of 2:1 AV block or bradycardia with a heart rate that is usually 70-80. (Normal fetal heart rate is 120-150.) In one instance, biventricular hypertrophy and biventricular dysfunction were seen on fetal echocardiogram [<xref ref-type="bibr" rid="timothy.REF.splawski.2005.8089">Splawski et al 2005</xref>].</p>
            <p><bold>Congenital heart defects</bold> are present in approximately 70% of individuals and include PDA, PFO, VSD, TOF, and HCM.</p>
            <table-wrap id="timothy.T.cardiac_phenotype_of_classic_t" position="anchor" orientation="portrait">
              <label>Table 2. </label>
              <caption>
                <p>Cardiac Phenotype of Classic Timothy Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Cardiac Phenotype</th>
                    <th id="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Affected&#x000a0;<sup>1</sup>/Evaluated</th>
                    <th id="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">%</th>
                    <th id="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Not Available</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">QTc prolongation</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">25/25</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">100</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">TWA</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">7/10</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">70</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">15</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Functional 2:1 AV block</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">17/21</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">81</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">4</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Tachyarrhythmias</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">21/25</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">84</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Congenital heart disease<break/>(PDA, PFO, VSD, TOF, HCM)</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">13/21</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">61</td>
                    <td headers="hd_h_timothy.T.cardiac_phenotype_of_classic_t_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">4</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn>
                  <p>TWA = T-wave alternance</p>
                </fn>
                <fn>
                  <p>PDA = patent ductus arteriosus</p>
                </fn>
                <fn>
                  <p>PFO = patent foramen ovale</p>
                </fn>
                <fn>
                  <p>VSD = ventricular septal defect</p>
                </fn>
                <fn>
                  <p>TOF = tetralogy of Fallot</p>
                </fn>
                <fn>
                  <p>HCM = hypertrophic cardiomyopathy</p>
                </fn>
                <fn id="timothy.TF.2.1">
                  <label>1. </label>
                  <p>n = 25 (13 males, 12 females)</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="timothy.Extracardiac_Manifestations">
            <title>Extracardiac Manifestations</title>
            <p><bold>Cutaneous syndactyly</bold> may involve fingers two (index), three (middle), four (ring), and five (little), and bilateral cutaneous syndactyly of toes two and three. Syndactyly may be unilateral or bilateral and involve fingers four and five only, fingers three through five, or fingers two through five.</p>
            <p>
              <bold>Craniofacial findings</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Low-set ears</p>
              </list-item>
              <list-item>
                <p>Depressed nasal bridge</p>
              </list-item>
              <list-item>
                <p>Premaxillary underdevelopment</p>
              </list-item>
              <list-item>
                <p>Baldness at birth and for the first two years of life, followed by thin scalp hair</p>
              </list-item>
              <list-item>
                <p>Small, widely spaced teeth and poor dental enamel with severe caries [<xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>]</p>
              </list-item>
            </list>
            <p><bold>Neuropsychiatric involvement</bold> occurs in approximately 80% of individuals. Developmental delays observed include language, motor, and generalized cognitive impairment. Children were impaired in all areas of adaptive function, including communication, socialization, and daily living skills. Some children did not produce speech sounds (babbling) during infancy; others had significant problems in articulation and receptive and expressive language. Profound developmental delay, intractable seizures, stroke, cortical blindness, and myopathy were reported in one individual [<xref ref-type="bibr" rid="timothy.REF.gillis.2012.182">Gillis et al 2012</xref>].</p>
            <p>Five children were formally evaluated for autism [<xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>]. Three met the diagnostic criteria, one met criteria for autism spectrum disorders, and one had severe delays in language development. Other children in this series were deceased or unavailable for evaluation. However, the association between autism spectrum disorders and Timothy syndrome was significant (p = 1.2x10<sup>-8</sup>). See <xref ref-type="table" rid="timothy.T.extracardiac_phenotype_of_timo">Table 3</xref>.</p>
            <p>
              <bold>Other findings</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Frequent infections (sinus, ear, respiratory) secondary to altered immune responses</p>
              </list-item>
              <list-item>
                <p>Intermittent hypoglycemia</p>
              </list-item>
              <list-item>
                <p>Joint contractures [<xref ref-type="bibr" rid="timothy.REF.gillis.2012.182">Gillis et al 2012</xref>]</p>
              </list-item>
            </list>
            <table-wrap id="timothy.T.extracardiac_phenotype_of_timo" position="anchor" orientation="portrait">
              <label>Table 3. </label>
              <caption>
                <p>Extracardiac Phenotype of Timothy Syndrome</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Extracardiac Phenotype</th>
                    <th id="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Affected&#x000a0;<sup>1</sup>/Evaluated</th>
                    <th id="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">%</th>
                    <th id="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Not Available</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cutaneous syndactyly</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">25/25</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">100</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">0</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Craniofacial findings&#x000a0;<sup>2</sup></td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">18/21</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">85</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">4</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Sepsis or severe infections</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">11/19</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">57</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">6</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Neuropsychiatric involvement</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">15/19</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">78</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">6</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Autism&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">3/10</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">30</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">15</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Autism spectrum disorder&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2/10</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">20</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">15</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Severe language delay&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">1/10</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">10</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">15</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Problems in social relationships + mild language delay&#x000a0;<sup>3</sup></td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">2/10</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">20</td>
                    <td headers="hd_h_timothy.T.extracardiac_phenotype_of_timo_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">15</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="timothy.TF.3.1">
                  <label>1. </label>
                  <p>n = 25: 13 males, 12 females</p>
                </fn>
                <fn id="timothy.TF.3.2">
                  <label>2. </label>
                  <p>Low-set ears, depressed nasal bridge, premaxillary underdevelopment, baldness at birth, thin scalp hair, small, widely spaced teeth</p>
                </fn>
                <fn id="timothy.TF.3.3">
                  <label>3. </label>
                  <p>Formal evaluation for autism was performed.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
          </sec>
          <sec id="timothy.Cause_of_Death">
            <title>Cause of Death</title>
            <p>Ventricular tachyarrhythmia (ventricular tachycardia and ventricular fibrillation), present in 80% of individuals, is the leading cause of death in Timothy syndrome. Average age at death in 14 of 25 children with classic Timothy syndrome was 2.5 years [<xref ref-type="bibr" rid="timothy.REF.reichenbach.1992.54">Reichenbach et al 1992</xref>; <xref ref-type="bibr" rid="timothy.REF.marks.1995a.744">Marks et al 1995a</xref>; <xref ref-type="bibr" rid="timothy.REF.marks.1995b.59">Marks et al 1995b</xref>; <xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>; <xref ref-type="bibr" rid="timothy.REF.loanjoe.2005.1365">Lo-A-Njoe et al 2005</xref>; Timothy 2005, personal communication; Bloise 2006, personal communication]. Two deaths reported were not related to tachyarrhythmi: one from severe infections (despite aggressive antibiotic therapy) and the other from complications of intractable hypoglycemia.</p>
          </sec>
        </sec>
        <sec id="timothy.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>The classic Timothy syndrome phenotype results from the <xref ref-type="table" rid="timothy.T.selected_cacna1c_pathogenic_al">p.Gly406Arg</xref> pathogenic variant in exon 8A, an exon contained in a specific splice variant of <italic toggle="yes">CACNA1C</italic> (see <xref ref-type="sec" rid="timothy.Molecular_Genetics">Molecular Genetics</xref>). Transcripts containing exon 8A are found in approximately 20% of all cardiac mRNAs. Compared to atypical Timothy syndrome (formerly referred to as type 2), classic Timothy syndrome has milder cardiac symptoms with an average QTc of 580 ms, rare multiple arrhythmias, and association of most arrhythmias with medications and/or anesthesia.</p>
          <p>In contrast, the two individuals with atypical (type 2) Timothy syndrome had pathogenic variants (p.Gly402Ser and p.Gly406Arg) in exon 8 of an alternate splice form that represents 80% of all cardiac mRNAs, resulting in a more severe phenotype than classic Timothy syndrome with an average QTc of 640 ms and multiple episodes of unprovoked arrhythmia [<xref ref-type="bibr" rid="timothy.REF.bloise.2007.502">Bloise et al 2007</xref>].</p>
          <p>The milder phenotype of the second individual with atypical Timothy syndrome reported by <xref ref-type="bibr" rid="timothy.REF.splawski.2005.8089">Splawski et al [2005]</xref> is attributed to somatic mosaicism (in which the pathogenic variant is present in some, not all, cells).</p>
          <p><xref ref-type="bibr" rid="timothy.REF.gillis.2012.182">Gillis et al [2012]</xref> reported a <italic toggle="yes">de novo</italic> (without confirmation of parental identity) novel <italic toggle="yes">CACNA1C</italic> pathogenic variant (<xref ref-type="table" rid="timothy.T.selected_cacna1c_pathogenic_al">p.Ala1473Gly</xref>) associated with a severe phenotype: profound developmental delay, intractable seizures, joint contractures, stroke, cortical blindness, and myopathy.</p>
        </sec>
        <sec id="timothy.Penetrance">
          <title>Penetrance</title>
          <p>No study has specifically investigated the issue of the penetrance of TS. Of note, however, penetrance was 100% in the 18 affected individuals with Timothy syndrome reported to date [<xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>, <xref ref-type="bibr" rid="timothy.REF.loanjoe.2005.1365">Lo-A-Njoe et al 2005</xref>, <xref ref-type="bibr" rid="timothy.REF.splawski.2005.8089">Splawski et al 2005</xref>] and it has remained very high (22 of 23 individuals with pathogenic variants had clearly abnormal electrocardiogram) in the two reports of gain-of-function <italic toggle="yes">CACN1C</italic> pathogenic variants in association with QT prolongation without extracardiac abnormalities [<xref ref-type="bibr" rid="timothy.REF.fukuyama.2014.1828">Fukuyama et al 2014</xref>, <xref ref-type="bibr" rid="timothy.REF.wemh_ner.2015.186">Wemh&#x000f6;ner et al 2015</xref>].</p>
        </sec>
        <sec id="timothy.Nomenclature">
          <title>Nomenclature</title>
          <p>Timothy syndrome is named after Katherine Timothy, who followed children with the disorder for more than 14 years, identifying the non-cardiac manifestations and collecting samples that led to the discovery of the gene in which pathogenic variants are causative.</p>
        </sec>
        <sec id="timothy.Prevalence">
          <title>Prevalence</title>
          <p>The prevalence of TS in not known. Its high mortality and severe manifestations point to a very low prevalence in the general population. Milder phenotypes of &#x0201c;isolated&#x0201d; QT prolongation associated with pathogenic variants in <italic toggle="yes">CACNA1C</italic> may have higher prevalence, although it has never been quantified.</p>
        </sec>
      </sec>
      <sec id="timothy.Genetically_Related_Allelic_Diso">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>It is important to note that the clinical phenotype associated with <italic toggle="yes">CACNA1C</italic> pathogenic variants can be highly variable.</p>
        <p><bold>Atypical Timothy syndrome.</bold> Originally reported in two individuals [<xref ref-type="bibr" rid="timothy.REF.splawski.2005.8089">Splawski et al 2005</xref>], atypical Timothy syndrome (formerly referred to as <bold>Timothy syndrome type 2</bold>) is characterized by:</p>
        <list list-type="bullet">
          <list-item>
            <p>Presence of extreme prolongation of the QT (QTc ranging from 620 to 730 ms), causing multiple arrhythmias and sudden death; and</p>
          </list-item>
          <list-item>
            <p>Absence of syndactyly.</p>
          </list-item>
        </list>
        <p>One child had severe intellectual disability and nemaline rods on muscle biopsy that were considered secondary to prolonged immobility rather than a primary muscle disorder.</p>
        <p><bold>Long QT syndrome (LQTS type 8).</bold>
<italic toggle="yes">CACNA1C</italic> pathogenic variants have been associated with a phenotype that is indistinguishable from that of a typical long QT syndrome (QT prolongation and propensity to ventricular arrhythmias in the absence of structural cardiac abnormalities and extracardiac manifestations) [<xref ref-type="bibr" rid="timothy.REF.fukuyama.2014.1828">Fukuyama et al 2014</xref>, <xref ref-type="bibr" rid="timothy.REF.wemh_ner.2015.186">Wemh&#x000f6;ner et al 2015</xref>]. The p.Gly402Ser variant has also been reported to cause isolated QTc prolongation and cardiac arrhythmias [<xref ref-type="bibr" rid="timothy.REF.splawski.2005.8089">Splawski et al 2005</xref>, <xref ref-type="bibr" rid="timothy.REF.hiippala.2015.629">Hiippala et al 2015</xref>] (see <xref ref-type="table" rid="timothy.T.selected_cacna1c_pathogenic_al">Table 4</xref> and <xref ref-type="sec" rid="timothy.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>).</p>
      </sec>
      <sec id="timothy.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <p><bold>Long QT syndrome (LQTS)</bold> is associated with tachyarrhythmias, including ventricular tachycardia, episodes of <italic toggle="yes">torsade de pointes</italic> (TdP) ventricular tachycardia, and ventricular fibrillation, which may culminate in syncope or sudden death. LQTS is typically inherited in an autosomal dominant manner.</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Nonsyndromic autosomal dominant LQTS</bold> is characterized by QT interval prolongation. The most common symptom is TdP, which causes a syncopal event and is usually self-terminating. Syncope typically occurs without warning. In some instances, TdP degenerates to ventricular fibrillation, cardiac arrest, and sudden death if the individual is not defibrillated. Approximately 50%-70% of individuals with a pathogenic variant in one of the genes associated with LQTS have symptoms; cardiac events may occur from infancy through middle age but are most common from the pre-teen years through the 20s.The clinical phenotype of an individual with a <italic toggle="yes">CACNA1C</italic> pathogenic variant but no extracardiac findings (i.e., LQTS type 8) can be indistinguishable from other forms of LQTS.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="acpp" document-type="chapter"><bold>Andersen-Tawil syndrome</bold></related-object>
<bold>(long QT syndrome type 7)</bold> is characterized by a triad of features: periodic paralysis (episodic flaccid muscle weakness); prolonged QT interval and ventricular arrhythmias; and dysmorphic features including low-set ears, wide-spaced eyes, small mandible, fifth-digit clinodactyly, syndactyly, short stature, and scoliosis. In the first or second decade, affected individuals present with either cardiac symptoms (palpitations and/or syncope) or weakness that occurs spontaneously following prolonged rest or following rest after exertion.Approximately 60% of individuals with Andersen-Tawil syndrome have a detectable pathogenic variant in <italic toggle="yes">KCNJ2</italic>, which encodes the inward rectifier potassium channel protein, Kir2.1. <italic toggle="yes">KCNJ2</italic> pathogenic variants may also cause a purely cardiac phenotype.Andersen-Tawil syndrome is inherited in an autosomal dominant manner. At least 50% of diagnosed individuals have an affected parent; the remaining cases are caused by <italic toggle="yes">de novo</italic> pathogenic variants.</p>
          </list-item>
          <list-item>
            <p><related-object link-type="booklink" source-id="gene" document-id="jln" document-type="chapter"><bold>Jervell and Lange-Nielsen syndrome</bold></related-object>
<bold>(JLNS)</bold> is characterized by congenital profound bilateral sensorineural hearing loss and LQTc usually greater than 500 msec. The classic presentation of JLNS is a deaf child who experiences syncopal episodes during periods of stress, exercise, or fright. More than half of untreated children with JLNS die prior to age 15 years.The genes in which pathogenic variants cause JLNS are <italic toggle="yes">KCNQ1</italic> and <italic toggle="yes">KCNE1</italic>; mutation of these genes can also cause a purely cardiac phenotype.JLNS is inherited in an autosomal recessive manner. Parents of a child with JLNS are typically heterozygous for a pathogenic variant in <italic toggle="yes">KCNQ1</italic> or <italic toggle="yes">KCNE1</italic>. Rarely, only one parent may be a carrier; and the other pathogenic variant may arise <italic toggle="yes">de novo</italic>. Parents may or may not have the LQTS phenotype.</p>
          </list-item>
        </list>
        <p><bold>Acquired causes of QT prolongation</bold> due to electrolyte imbalance (e.g., hypokalemia) or QT-prolonging drugs (e.g., macrolide antibiotics) should be excluded before considering Timothy syndrome diagnosis. In such cases the removal of the offending agent should lead to ECG normalization. However, some cases of drug-induced QT prolongation may also have a genetic predisposition (including pathogenic variants in long QT syndrome genes).</p>
        <p><bold>Syndactyly.</bold> Cutaneous syndactyly of the fingers and cutaneous syndactyly of toes two and three can both be seen in numerous disorders. The latter is seen in <related-object link-type="booklink" source-id="gene" document-id="bbs" document-type="chapter">Bardet-Biedl syndrome</related-object> and <related-object link-type="booklink" source-id="gene" document-id="slo" document-type="chapter">Smith-Lemli-Opitz syndrome</related-object>, in which it can be a significant clue to diagnosis.</p>
        <p><bold>Autism.</bold> See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/phenotypicSeries/PS209850">OMIM</ext-link>.</p>
        <p>See <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.omim.org/phenotypicSeries/PS192500?sort=phenotype">Long QT syndrome: OMIM Phenotypic Series</ext-link> to view genes associated with this phenotype in OMIM.</p>
      </sec>
      <sec id="timothy.Management">
        <title>Management</title>
        <sec id="timothy.Evaluations_Following_Initial_Di">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with Timothy syndrome, the following evaluations are recommended:</p>
          <list list-type="bullet">
            <list-item>
              <p>Electrocardiogram</p>
            </list-item>
            <list-item>
              <p>Echocardiogram</p>
            </list-item>
            <list-item>
              <p>Developmental and neurologic assessment</p>
            </list-item>
            <list-item>
              <p>Orthopedist consulation for skeletal abnormalities</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="timothy.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Note: All medical procedures requiring anesthesia should be performed with caution (see <xref ref-type="sec" rid="timothy.Prevention_of_Secondary_Complica">Prevention of Secondary Complications</xref>).</p>
          <p>
            <bold>Long QT interval</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Beta-blockers. While most individuals with Timothy syndrome are treated with beta-blockers to maintain QT interval stability and thereby prevent ventricular tachyarrhythmia, no data concerning the effectiveness of beta-blockers are available. Verapamil and ranolazine have been reported effective in case reports. However, no cohort-based analysis of the efficacy of pharmacologic therapy is available.</p>
            </list-item>
            <list-item>
              <p>Pacemaker. To control 2:1 AV block and resultant bradycardia, a pacemaker can be placed with general success within the first days of life.</p>
            </list-item>
            <list-item>
              <p>Implants. The implantable cardioverter defibrillator is most important in preventing sudden cardiac death in individuals with Timothy syndrome. An implant should be considered in every individual with confirmed diagnosis as soon as body weight allows the procedure (as determined by the treating clinician).</p>
            </list-item>
          </list>
          <p><bold>Congenital heart defects.</bold> Standard treatment is indicated.</p>
          <p><bold>Respiratory infections.</bold> Standard treatment (antibiotic therapy, steroids) is indicated. The possibility of reduced immune response should be considered.</p>
          <p><bold>Surgical release of syndactyly.</bold> Standard treatment is indicated.</p>
        </sec>
        <sec id="timothy.Prevention_of_Primary_Manifestat">
          <title>Prevention of Primary Manifestations</title>
          <p>Arrhythmias in Timothy syndrome must be prevented with the standard therapy described in <xref ref-type="sec" rid="timothy.Treatment_of_Manifestations">Treatment of Manifestations</xref>.</p>
        </sec>
        <sec id="timothy.Prevention_of_Secondary_Complica">
          <title>Prevention of Secondary Complications</title>
          <p>Anesthesia is a known trigger for cardiac arrhythmia in individuals with Timothy syndrome. Therefore, any surgical intervention must be performed under close cardiac monitoring. Because clinical experience with Timothy syndrome is scarce, all compounds used for general anesthesia should be regarded as potentially dangerous.</p>
          <p>Prevention of extracardiac complications (including use of appropriate antibiotic prophylaxis/therapy before surgical intervention) must always be considered.</p>
        </sec>
        <sec id="timothy.Surveillance">
          <title>Surveillance</title>
          <p>Surveillance includes the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Monitoring of serum glucose concentrations, especially in individuals treated with beta-blockers, which may mask hypoglycemic symptoms</p>
            </list-item>
            <list-item>
              <p>A complete cardiac evaluation based on the status of the individual patient</p>
            </list-item>
          </list>
        </sec>
        <sec id="timothy.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>The following should be avoided:</p>
          <list list-type="bullet">
            <list-item>
              <p>All drugs reported to prolong QT interval (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.crediblemeds.org/">CredibleMeds</ext-link><sup>&#x000ae;</sup>)</p>
            </list-item>
            <list-item>
              <p>Drugs and dietary practices that could lead to hypoglycemia</p>
            </list-item>
          </list>
        </sec>
        <sec id="timothy.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>Using molecular genetic testing for the <italic toggle="yes">CACNA1C</italic> pathogenic variants found in the proband, it is appropriate to evaluate the older and younger sibs of a proband in order to identify as early as possible those who would benefit from institution of treatment and preventive measures.</p>
          <p>See <xref ref-type="sec" rid="timothy.Related_Genetic_Counseling_Issue">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="timothy.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Pharmacologic therapies under investigation to shorten ventricular repolarization, restore one-to-one conduction, and reduce the risk of arrhythmias include sodium channel blockers and calcium channel blockers. Although verapamil has been used in one case [<xref ref-type="bibr" rid="timothy.REF.jacobs.2006.967">Jacobs et al 2006</xref>] and the partial effectiveness of sodium channel blockers mexiletine and ranolazine has been reported for two patients [<xref ref-type="bibr" rid="timothy.REF.shah.2012.e62">Shah et al 2012</xref>, <xref ref-type="bibr" rid="timothy.REF.gao.2013.614">Gao et al 2013</xref>], no data are available to support their routine use in Timothy syndrome.</p>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov/">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions.</p>
        </sec>
      </sec>
      <sec id="timothy.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="timothy.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>Timothy syndrome is inherited in an autosomal dominant manner. Although Timothy syndrome has been reported to result from parental germline mosaicism, it is usually the result of a <italic toggle="yes">de novo</italic> pathogenic variant in <italic toggle="yes">CACNA1C</italic>.</p>
        </sec>
        <sec id="timothy.Risk_to_Family_Members">
          <title>Risk to Family Members</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>To date, none of the individuals diagnosed with Timothy syndrome has had an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with Timothy syndrome usually has the disorder as the result of a <italic toggle="yes">de novo</italic> pathogenic variant, but may have it as the result of parental germline mosaicism.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include molecular genetic testing of several tissues, including sperm, for the <italic toggle="yes">CACNA1C</italic> pathogenic variant identified in the proband.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband's parents.</p>
            </list-item>
            <list-item>
              <p>Germline mosaicism has been observed:</p>
              <list list-type="bullet">
                <list-item>
                  <p>Two affected sibs had an unaffected mother [<xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>].</p>
                </list-item>
                <list-item>
                  <p>In a family with one affected child, syndactyly was suspected on fetal ultrasound examination in a subsequent pregnancy. Molecular genetic testing of cells obtained by amniocentesis identified the <italic toggle="yes">CACNA1C</italic> pathogenic variant in the fetus. The pregnancy was interrupted and syndactyly was confirmed [Bloise, unpublished observation].</p>
                </list-item>
              </list>
            </list-item>
            <list-item>
              <p>Timothy syndrome typically occurs as the result of a <italic toggle="yes">de novo</italic> pathogenic variant, and thus the risk to the sibs of a proband is small. However, because parental germline mosaicism occurs [<xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>], the sibs of a proband may be at increased risk of inheriting a <italic toggle="yes">CACNA1C</italic> pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> No individuals with Timothy syndrome have been reported to live long enough to reproduce.</p>
          <p><bold>Other family members of a proband.</bold> Because Timothy syndrome occurs as a result of either a <italic toggle="yes">de novo</italic> pathogenic variant or parental germline mosaicism, family members other than (possibly) the sibs of a proband are not at increased risk.</p>
        </sec>
        <sec id="timothy.Related_Genetic_Counseling_Issue">
          <title>Related Genetic Counseling Issues</title>
          <p>See Management, <xref ref-type="sec" rid="timothy.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</xref> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p>
          <p><bold>Family planning.</bold> The optimal time for determination of genetic risk and discussion of the availability of prenatal testing is before pregnancy.</p>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="timothy.Prenatal_Testing_and_Preimplanta">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p><bold>Molecular genetic testing.</bold> Once the <italic toggle="yes">CACNA1C</italic> pathogenic variant has been identified in an affected family member, prenatal testing and preimplantation genetic diagnosis for a pregnancy at increased risk for Timothy syndrome are possible options.</p>
          <p><bold>Fetal echocardiography.</bold> Because sibs could be affected in the case of parental mosaicism (see <xref ref-type="sec" rid="timothy.Risk_to_Family_Members">Risk to Family Members</xref>, <bold>Sibs of a proband</bold>), monitoring of cardiac rate and function during pregnancy is appropriate.</p>
        </sec>
      </sec>
      <sec id="timothy.Resources">
        <title>Resources</title>
      </sec>
      <sec id="timothy.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="timothy.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>Excitable cells contain voltage-dependent calcium channels that can dramatically increase cytosolic Ca<sup>2+</sup>. In heart and brain, the L-type calcium channel Ca<sub>V</sub>1.2 <italic toggle="yes">(CACNA1C</italic>, &#x003b1;<sub>1C</sub>, &#x003b1;<sub>1</sub>1.2) mediates this process.</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">CACNA1C</italic> comprises 50 exons and spans approximately 700 kb on the human chromosome 12; it has a complex genomic structure that undergoes extensive alternative splicing producing at least 36 different transcripts. Alternative splicing is regulated by a number of different factors including a tissue-specific regulation [<xref ref-type="bibr" rid="timothy.REF.napolitano.2011.607">Napolitano &#x00026; Antzelevitch 2011</xref>]. This may explain the variability of the clinical phenotypes associated with pathogenic variants occurring in alternatively spliced exons or in different regions of the protein. For a detailed summary of gene and protein information, see <related-object source-id="gene" document-id="timothy" object-id="timothy.molgen.TA">Table A</related-object>.</p>
          <p><bold>Pathogenic allelic variants.</bold> In Timothy syndrome, the original pathogenic variant observed was p.Gly406Arg, located in alternatively spliced exon 8A (reference sequence NM_000719.6), encoding transmembrane segment S6 of domain I [<xref ref-type="bibr" rid="timothy.REF.splawski.2004.19">Splawski et al 2004</xref>].</p>
          <p>In atypical Timothy syndrome (type 2), <italic toggle="yes">de novo</italic> missense pathogenic variants were identified in exon 8 of an <italic toggle="yes">CACNA1C</italic> alternate splice form (reference sequence NM_001167625.1). Of the two reported pathogenic variants, one was analogous to that found in exon 8A in classic Timothy syndrome (type 1), p.Gly406Arg. The other pathogenic variant was p.Gly402Ser [<xref ref-type="bibr" rid="timothy.REF.splawski.2005.8089">Splawski et al 2005</xref>].</p>
          <p>The pathogenic variants in exon 8 and 8A of the <italic toggle="yes">CACNA1C</italic> alternate splice forms are located in the terminal part of transmembrane segment 6 in domain I of the predicted protein topology. The p.Ala1473Gly variant identified by <xref ref-type="bibr" rid="timothy.REF.gillis.2012.182">Gillis et al [2012]</xref> is located at the end of transmembrane segment 6 in domain IV. Other <italic toggle="yes">CACNA1C</italic> pathogenic variants identified in cases of QT interval prolongation in the absence of other typical TS phenotypes are p.Arg858His and p.Ala582Asp [<xref ref-type="bibr" rid="timothy.REF.fukuyama.2014.1828">Fukuyama et al 2014</xref>]. Residue 856 is located in the intracellular loop between domains II and III; 582 is in the loop between segments 2 and 3 of domain II. Overall, it appears that all gain-of-function variants identified in <italic toggle="yes">CACAN1C</italic> are located in the intracellular side of the protein.</p>
          <p>The mechanism of arrhythmia is reduced Ca<sub>V</sub>1.2 channel inactivation, leading to maintained depolarizing Ca<sup>2+</sup> currents during the plateau phase of the cardiac action potential. There is relatively little outward current during the plateau phase, so even modest changes in inward calcium current lead to significant QT interval prolongation. This prolongation in turn leads to increased risk of spontaneous, abnormal secondary depolarizations (so-called &#x0201c;after-depolarizations&#x0201d;), arrhythmia, and sudden death.</p>
          <table-wrap id="timothy.T.selected_cacna1c_pathogenic_al" position="anchor" orientation="portrait">
            <label>Table 4. </label>
            <caption>
              <p>Selected <italic toggle="yes">CACNA1C</italic> Pathogenic Allelic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change</th>
                  <th id="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Protein Amino Acid Change</th>
                  <th id="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1204G&#x0003e;A</td>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly402Ser</td>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_3" rowspan="3" valign="middle" align="left" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NM_000719.6">NM_000719.6</ext-link>&#x000a0;<sup>1</sup>
<break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/entrez/viewer.fcgi?val=NP_000710.5">NP_000710.5</ext-link></td>
                </tr>
                <tr>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1216G&#x0003e;A</td>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly406Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.4418C&#x0003e;G</td>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Ala1473Gly</td>
                </tr>
                <tr>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">c.1216G&#x0003e;A</td>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">p.Gly406Arg</td>
                  <td headers="hd_h_timothy.T.selected_cacna1c_pathogenic_al_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/115583676?report=genbank">NM_001167625.1</ext-link>&#x000a0;<sup>2</sup><break/><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_001161097.1">NP_001161097.1</ext-link></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="timothy.TF.4.1">
                <label>1. </label>
                <p>Contains exon 8A</p>
              </fn>
              <fn id="timothy.TF.4.2">
                <label>2. </label>
                <p>Contains exon 8</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">CACNA1C</italic> encodes Ca<sub>V</sub>1.2, the cardiac L-type calcium channel, which is important for excitation and contraction of the heart. In Ca<sub>V</sub>1.2, transmembrane segment 6 of domain I (D1/S6) can be encoded by two mutually exclusive exons, 8 and 8A. The spliced form of Ca<sub>V</sub>1.2 containing exon 8 is highly expressed in heart and brain, accounting for approximately 80% of Ca<sub>V</sub>1.2 mRNAs.</p>
          <p><bold>Abnormal gene product.</bold> The pathogenic variants p.Gly406Arg and p.Gly402Ser cause reduced channel inactivation, resulting in maintained depolarizing L-type calcium currents. Computer modeling showed prolongation of cardiomyocyte action potentials and delayed after-depolarizations, factors that increase the risk of arrhythmia. These data indicate that gain-of-function variants of Ca<sub>V</sub>1.2 exons 8 and 8A cause distinct forms of Timothy syndrome.</p>
          <p>Ca<sub>V</sub>1.2 with exon 8 is highly expressed in heart and brain, consistent with the severe cardiac and cognitive defects associated with the two pathogenic variants that occur in exon 8 [<xref ref-type="bibr" rid="timothy.REF.splawski.2005.8089">Splawski et al 2005</xref>].</p>
        </sec>
      </sec>
      <sec id="timothy.References">
        <title>References</title>
        <sec id="timothy.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="timothy.Literature_Cited.reflist0">
            <ref id="timothy.REF.bloise.2007.502">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bloise</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Napolitano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timothy</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pontes Cavalcanti</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szepesvary</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Drago</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nastoli</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Splawski</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keating</surname>
                    <given-names>MT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Priori</surname>
                    <given-names>SG</given-names>
                  </name>
                </person-group>
                <article-title>Clinical profile and risk of sudden death in children with Timothy syndrome.</article-title>
                <source>Circulation</source>
                <year>2007</year>
                <volume>114</volume>
                <supplement>suppl II</supplement>
                <fpage>502</fpage>
              </element-citation>
            </ref>
            <ref id="timothy.REF.fukuyama.2014.1828">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fukuyama</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kato</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ohno</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ding</surname>
                    <given-names>WG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toyoda</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Itoh</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kimura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makiyama</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ito</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Matsuura</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horie</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Long QT syndrome type 8: novel CACNA1C mutations causing QT prolongation and variant phenotypes.</article-title>
                <source>Europace.</source>
                <year>2014</year>
                <volume>16</volume>
                <fpage>1828</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">24728418</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.gao.2013.614">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Xue</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hu</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liu</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sun</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timothy</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yan</surname>
                    <given-names>GX</given-names>
                  </name>
                </person-group>
                <article-title>Inhibition of late sodium current by mexiletine: a novel pharmotherapeutical approach in timothy syndrome.</article-title>
                <source>Circ Arrhythm Electrophysiol.</source>
                <year>2013</year>
                <volume>6</volume>
                <fpage>614</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">23580742</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.gillis.2012.182">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gillis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burashnikov</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antzelevitch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blaser</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gross</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turner</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Babul-Hirji</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chitayat</surname>
                    <given-names>D.</given-names>
                  </name>
                </person-group>
                <article-title>Long QT, syndactyly, joint contractures, stroke and novel CACNA1C mutation: expanding the spectrum of Timothy syndrome.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2012</year>
                <volume>158A</volume>
                <fpage>182</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">22106044</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.hiippala.2015.629">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hiippala</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tallila</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Myllykangas</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koskenvuo</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alastalo</surname>
                    <given-names>TP</given-names>
                  </name>
                </person-group>
                <article-title>Expanding the phenotype of Timothy syndrome type 2: an adolescent with ventricular fibrillation but normal development.</article-title>
                <source>Am J Med Genet A.</source>
                <year>2015</year>
                <volume>167A</volume>
                <fpage>629</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">25691416</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.jacobs.2006.967">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Jacobs</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Knight</surname>
                    <given-names>BP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McDonald</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burke</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Verapamil decreases ventricular tachyarrhythmias in a patient with Timothy syndrome (LQT8).</article-title>
                <source>Heart Rhythm.</source>
                <year>2006</year>
                <volume>3</volume>
                <fpage>967</fpage>
                <lpage>70</lpage>
                <pub-id pub-id-type="pmid">16876748</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.loanjoe.2005.1365">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lo-A-Njoe</surname>
                    <given-names>SM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilde</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Erven</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blom</surname>
                    <given-names>NA</given-names>
                  </name>
                </person-group>
                <article-title>Syndactyly and long QT syndrome (CaV1.2 missense mutation G406R) is associated with hypertrophic cardiomyopathy.</article-title>
                <source>Heart Rhythm.</source>
                <year>2005</year>
                <volume>2</volume>
                <fpage>1365</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16360093</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.marks.1995a.744">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marks</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Trippel</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keating</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Long QT syndrome associated with syndactyly identified in females.</article-title>
                <source>Am J Cardiol.</source>
                <year>1995a</year>
                <volume>76</volume>
                <fpage>744</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">7572644</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.marks.1995b.59">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Marks</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Whisler</surname>
                    <given-names>SL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clericuzio</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keating</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>A new form of long QT syndrome associated with syndactyly.</article-title>
                <source>J Am Coll Cardiol.</source>
                <year>1995b</year>
                <volume>25</volume>
                <fpage>59</fpage>
                <lpage>64</lpage>
                <pub-id pub-id-type="pmid">7798527</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.napolitano.2011.607">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Napolitano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Antzelevitch</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <article-title>Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac voltage-dependent L-type calcium channel.</article-title>
                <source>Circ Res.</source>
                <year>2011</year>
                <volume>108</volume>
                <fpage>607</fpage>
                <lpage>18</lpage>
                <pub-id pub-id-type="pmid">21372292</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.reichenbach.1992.54">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Reichenbach</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meister</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Theile</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>The heart-hand syndrome. A new variant of disorders of heart conduction and syndactylia including osseous changes in hands and feet</article-title>
                <source>Kinderarztl Prax.</source>
                <year>1992</year>
                <volume>60</volume>
                <fpage>54</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">1318983</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.shah.2012.e62">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Shah</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baez-Escudero</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weisberg</surname>
                    <given-names>IL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beshai</surname>
                    <given-names>JF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burke</surname>
                    <given-names>MC</given-names>
                  </name>
                </person-group>
                <article-title>Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8).</article-title>
                <source>Pacing Clin Electrophysiol.</source>
                <year>2012</year>
                <volume>35</volume>
                <fpage>e62</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">20883512</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.splawski.2005.8089">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Splawski</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timothy</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decher</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sachse</surname>
                    <given-names>FB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beggs</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanguinetti</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keating</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Severe arrhythmia disorder caused by cardiac L-type calcium channel mutations.</article-title>
                <source>Proc Natl Acad Sci U S A.</source>
                <year>2005</year>
                <volume>102</volume>
                <fpage>8089</fpage>
                <lpage>96</lpage>
                <pub-id pub-id-type="pmid">15863612</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.splawski.2004.19">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Splawski</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Timothy</surname>
                    <given-names>KW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharpe</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decher</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kumar</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bloise</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Napolitano</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Joseph</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Condouris</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tager-Flusberg</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Priori</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sanguinetti</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keating</surname>
                    <given-names>MT</given-names>
                  </name>
                </person-group>
                <article-title>Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism.</article-title>
                <source>Cell.</source>
                <year>2004</year>
                <volume>119</volume>
                <fpage>19</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">15454078</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.wemh_ner.2015.186">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wemh&#x000f6;ner</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Friedrich</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stallmeyer</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Coffey</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Grace</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zumhagen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Seebohm</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ortiz-Bonnin</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinn&#x000e9;</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sachse</surname>
                    <given-names>FB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schulze-Bahr</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Decher</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <article-title>Gain-of-function mutations in the calcium channel CACNA1C (Cav1.2) cause non-syndromic long-QT but not Timothy syndrome.</article-title>
                <source>J Mol Cell Cardiol.</source>
                <year>2015</year>
                <volume>80</volume>
                <fpage>186</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">25633834</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="timothy.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="timothy.Suggested_Reading.reflist0">
            <ref id="timothy.REF.sung.2010.h33">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sung</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>YH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lai</surname>
                    <given-names>NH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Teng</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luo</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tien</surname>
                    <given-names>HC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lo</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>SN</given-names>
                  </name>
                </person-group>
                <article-title>Beta-adrenergic modulation of arrhythmogenesis and identification of targeted sites of antiarrhythmic therapy in Timothy (LQT8) syndrome: a theoretical study.</article-title>
                <source>Am J Physiol Heart Circ Physiol.</source>
                <year>2010</year>
                <volume>298</volume>
                <fpage>H33</fpage>
                <lpage>44</lpage>
                <pub-id pub-id-type="pmid">19855067</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.thiel.2008.2225">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Thiel</surname>
                    <given-names>WH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hund</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koval</surname>
                    <given-names>OM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Purohit</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Song</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mohler</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>ME</given-names>
                  </name>
                </person-group>
                <article-title>Proarrhythmic defects in Timothy syndrome require calmodulin kinase II.</article-title>
                <source>Circulation.</source>
                <year>2008</year>
                <volume>118</volume>
                <fpage>2225</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">19001023</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.yarotskyy.2009.551">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yarotskyy</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gao</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peterson</surname>
                    <given-names>BZ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elmslie</surname>
                    <given-names>KS</given-names>
                  </name>
                </person-group>
                <article-title>The Timothy syndrome mutation of cardiac CaV1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation.</article-title>
                <source>J Physiol.</source>
                <year>2009</year>
                <volume>587</volume>
                <fpage>551</fpage>
                <lpage>65</lpage>
                <pub-id pub-id-type="pmid">19074970</pub-id>
              </element-citation>
            </ref>
            <ref id="timothy.REF.yazawa.2011.230">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Yazawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hsueh</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jia</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pasca</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bernstein</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallmayer</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dolmetsch</surname>
                    <given-names>RE</given-names>
                  </name>
                </person-group>
                <article-title>Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome.</article-title>
                <source>Nature.</source>
                <year>2011</year>
                <volume>471</volume>
                <fpage>230</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">21307850</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="timothy.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="timothy.Acknowledgments">
          <title>Acknowledgments</title>
          <p>We are grateful to all of the individuals with Timothy syndrome and their families for donated time and samples. We would also like to thank the physicians who identified and are providing care for individuals with Timothy syndrome.</p>
        </sec>
        <sec id="timothy.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>16 July 2015 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>21 April 2011 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>20 August 2009 (cd) Revision: prenatal diagnosis available clinically</p>
            </list-item>
            <list-item>
              <p>27 January 2009 (cd) Revision: sequence analysis available clinically</p>
            </list-item>
            <list-item>
              <p>29 July 2008 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>15 February 2006 (me) Review posted to live Web site</p>
            </list-item>
            <list-item>
              <p>5 July 2005 (is) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
